Successful insertion and expression of a tetracycline transactivator in Anopheles stephensi associated with increased egg production and decreased hatching rate
- PMID: 41152980
- PMCID: PMC12570488
- DOI: 10.1186/s13071-025-07003-7
Successful insertion and expression of a tetracycline transactivator in Anopheles stephensi associated with increased egg production and decreased hatching rate
Abstract
Background: Sanaria® has pioneered production of aseptic, purified, vialed cryopreserved Plasmodium falciparum (Pf) sporozoites (SPZ) as vaccines and for controlled human malaria infections. More than 3500 individuals have received more than 9700 injections of PfSPZ worldwide. The PfSPZ are manufactured in aseptically reared female Anopheles stephensi mosquitoes. Since PfSPZ vaccines are intended primarily for some of the most disadvantaged people in the world, keeping costs low is imperative. One approach to reducing the cost of goods is to eliminate male mosquitoes from the production process, thereby doubling the numbers of PfSPZ-producing mosquitoes per unit space. We intend to do this by creating An. stephensi with a male-lethal allele controlled by the tetracycline conditional gene expression system.
Methods: Herein, we report the first step in this process, the creation of a driver line that expresses the reverse tetracycline transactivator (rtTA).
Results: After suboptimal results using the bZip early embryonic promoter, we produced three mosquito driver lines that expressed rtTA from three different genomic loci under the early embryonic vasa promoter. Expressing the rtTA under the vasa promoter significantly increased rtTA mRNA levels compared with under bZip. We were unable to achieve homozygosity in two of these lines even after 26 generations. In a third line we observed seven distinct insertions, six of which, including one located in an intron of a protein-coding gene, were homozygous. This line achieved homozygosity after being passed through seven generations, suggesting that the insertions did not disrupt the function of any crucial genomic locus. The levels of rtTA mRNA expression in the homozygous-viable line were higher than those in the other two lines, reinforcing the idea that the inability to reach homozygosity was not due to rtTA expression levels but rather the position of the insertion. The homozygous-viable line produced ~18% more eggs per female, and a hatching rate of larvae from eggs was 39% lower than that of wild-type An. stephensi. The next step will be to cross the driver line with an effector line containing a male-linked lethal gene regulated by the tetracycline responsive element (TRE).
Keywords: Anopheles; Driver line; Tetracycline; rtTA.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethical approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: E.I., T.V.P, G.J., and S.L.H. are salaried employees of Sanaria Inc., the developer and owner of PfSPZ vaccines, and A.E.G. and P.F.B. were salaried employees of Sanaria Inc. when the work was performed. S.L.H. has a financial interest in Sanaria Inc. No other authors have competing interests.
Figures
Update of
-
Successful insertion and expression of a tetracycline transactivator in Anopheles stephensi associated with increased egg production and decreased hatching rate.Res Sq [Preprint]. 2025 Apr 16:rs.3.rs-6270709. doi: 10.21203/rs.3.rs-6270709/v1. Res Sq. 2025. Update in: Parasit Vectors. 2025 Oct 28;18(1):433. doi: 10.1186/s13071-025-07003-7. PMID: 40321780 Free PMC article. Updated. Preprint.
References
-
- Vector-borne diseases. World Health Organization 2024. https://www.who.int/news-room/fact-sheets/detail/vector-borne-diseases#:.... Accessed 26 Sept 2024.
-
- Sissoko MS, Healy SA, Katile A, Omaswa F, Zaidi I, Gabriel EE, et al. Safety and efficacy of PfSPZ vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis. 2017;17:498–509. - DOI - PMC - PubMed
-
- Olotu A, Urbano V, Hamad A, Eka M, Chemba M, Nyakarungu E, et al. Advancing global health through development and clinical trials partnerships: a randomized, placebo-controlled, double-blind assessment of safety, tolerability, and immunogenicity of Plasmodiumfalciparum sporozoites vaccine for malaria in healthy equatoguinean men. Am J Trop Med Hyg. 2018;98:308–18. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
